'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 32
Dec 08, 2016: Citius Moves Forward with Mino-Lok Phase 3 Trial 32
Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4 32
Nov 08, 2016: HKU Chemists achieve breakthrough in antibacterial drug research 33
Oct 26, 2016: Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016 33
Oct 20, 2016: MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA 34
Oct 18, 2016: Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV (telavancin), Including Ongoing TOUR Observational Patient Registry, at IDWeek 2016 35
Oct 04, 2016: Online Media Group covers Phase 3 clinical Trial 35
Clinical Trial Profile Snapshots 37
Appendix 174
Abbreviations 174
Definitions 174
Research Methodology 175
Secondary Research 175
About GlobalData 176
Contact Us 176
Disclaimer 176
Source 177
List of Tables
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2016* 6
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 18
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
List of Figures
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
GlobalData Methodology 175